Coya Therapeutics, Inc. (NASDAQ:COYA) Stock Has Average Target Price of $15.33 According to Brokerages

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have received an average rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $15.00.

A number of research firms have weighed in on COYA. Chardan Capital restated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday, August 12th. HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a research report on Friday, September 25th. Roth Capital reiterated a “buy” rating and set a $12.00 price objective on shares of Coya Therapeutics in a research note on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a report on Thursday, October 15th. Finally, BTIG Research reissued a “buy” rating and issued a $16.00 target price on shares of Coya Therapeutics in a research note on Tuesday, September 15th.

Institutional Trading of Coya Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in COYA. Cetera Investment Advisers grew its position in shares of Coya Therapeutics by 36.4% in the 1st quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after acquiring an additional 8,000 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Coya Therapeutics during the 1st quarter worth about $161,000. Dimensional Fund Advisors LP increased its stake in shares of Coya Therapeutics by 205.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 95,919 shares of the company’s stock worth $377,000 after purchasing an additional 64,490 shares during the last quarter. Long Corridor Asset Management Ltd bought a new stake in shares of Coya Therapeutics in the 2nd quarter valued at about $227,000. Finally, Allworth Financial LP raised its holdings in shares of Coya Therapeutics by 1,200.0% in the 2nd quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock valued at $76,000 after purchasing an additional 12,000 shares during the period. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Price Performance

Coya Therapeutics stock opened at $3.16 on Wednesday. The firm has a 50-day moving average of $4.37 and a 200-day moving average of $4.60. Coya Therapeutics has a one year low of $2.72 and a one year high of $6.62. The company has a market cap of $74.13 million, a price-to-earnings ratio of -2.95 and a beta of 0.70.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Tuesday, November 10th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.11). Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. The company had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.11 million. As a group, sell-side analysts expect that Coya Therapeutics will post -1.34 earnings per share for the current year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction. The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.